Sold as Serpasil, Rau-Sed, Sandril, Serpanray, Serpate and 4 more. Every FDA application for this active ingredient: 17 branded and 23 generic.
As of Nov 14, 2026, FDA lists 40 applications for Reserpine (sold as Serpasil, Rau-Sed, Sandril and others), first approved Aug 13, 1954, with 0 new uses approved and 0 published complete response letters.
| Aug 13, 1954 | SerpasilNDA 9434 · New dosage form | Novartis | 2 | Discontinued |
| Mar 24, 1955 | ReserpineNDA 9838 · New formulation or manufacturer | Sandoz | 5 | Discontinued |
| Aug 12, 1955 | SerpasilNDA 9115 · New active ingredient | Novartis | 0 | Discontinued |
| Oct 12, 1955 | SerpalanNDA 10124 · New formulation or manufacturer | Lannett | 3 | Discontinued |
| Dec 22, 1971 | ReserpineANDA 80393 | Watson Labs | 1 | Discontinued |
| Jan 19, 1972 | ReserpineANDA 80679 | Watson Labs | 1 | Discontinued |
| Mar 30, 1972 | ReserpineANDA 80525 | Mk Labs | 0 | Discontinued |
| Apr 4, 1972 | ReserpineANDA 80446 | Solvay | 0 | Discontinued |
| Jun 21, 1972 | ReserpineANDA 80457 | Halsey | 0 | Discontinued |
| Oct 16, 1972 | ReserpineANDA 80721 | Barr | 0 | Discontinued |
| Dec 26, 1972 | ReserpineANDA 80975 | Hikma | 3 | Discontinued |
| Apr 25, 1973 | ReserpineANDA 80749 | Watson Labs | 1 | Discontinued |
| Jul 31, 1973 | ReserpineANDA 80723 | Whiteworth Town Plsn | 0 | Discontinued |
| Aug 7, 1973 | ReserpineANDA 80492 | Marshall Pharma | 0 | Discontinued |
| Mar 11, 1977 | ReserpineANDA 85401 | Watson Labs | 0 | Discontinued |
| Mar 7, 1985 | ReserpineANDA 89020 | Teva | 1 | Discontinued |
| Mar 7, 1985 | ReserpineANDA 89019 | Teva | 0 | Discontinued |
| — | SerpateNDA 9453 | Vale | 0 | Discontinued |
| — | Rau-SedNDA 9357 | Bristol Myers Squibb | 0 | Discontinued |
| — | SandrilNDA 9376 | Lilly | 0 | Discontinued |
| — | SerpanrayNDA 9391 | Panray | 0 | Discontinued |
| — | ReserpineNDA 9627 | Impax Labs | 0 | Discontinued |
| — | HiserpiaNDA 9631 | Bowman Pharms | 0 | Discontinued |
| — | SerpiviteNDA 9645 | Vitarine | 0 | Discontinued |
| — | ReserpineNDA 9663 | Bundy | 0 | Discontinued |
| — | ReserpineNDA 9667 | Valeant Pharm Intl | 3 | Discontinued |
| — | ReserpineNDA 9859 | Cycle | 0 | Discontinued |
| — | SandrilNDA 10012 | Lilly | 2 | Discontinued |
| — | ReserpineNDA 10441 | Everylife | 2 | Discontinued |
| — | ReserpineNDA 11185 | Ivax Sub Teva Pharms | 0 | Discontinued |
| — | ReserpineANDA 84974 | Mylan | 0 | Discontinued |
| — | ReserpineANDA 80637 | Rexall | 0 | Discontinued |
| — | ReserpineANDA 80582 | Pvt Form | 0 | Discontinued |
| — | ReserpineANDA 80753 | Purepac Pharm | 0 | Discontinued |
| — | ReserpineANDA 83058 | Bell Pharma | 0 | Discontinued |
| — | ReserpineANDA 83145 | Elkins Sinn | 0 | Discontinued |
| — | ReserpineANDA 84663 | Pharmavite | 0 | Discontinued |
| — | ReserpineANDA 85207 | Tablicaps | 0 | Discontinued |
| — | ReserpineANDA 85775 | Pvt Form | 0 | Discontinued |
| — | ReserpineANDA 86117 | Pvt Form | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA